Zibotentan and Dapagliflozin combination, EvAluated in Liver cirrhosis (ZEAL study)

Trial Identifier: D4326C00003
Sponsor: AstraZeneca
NCTID:: NCT05516498
Start Date: October 2022
Primary Completion Date: November 2024
Study Completion Date: November 2024

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
AT Wien, AT, 1090
BE Edegem, BE, 2650
CH Bern, CH, 3010
CH Lugano, CH, 6900
DE Dresden, DE, 01307
DE Jena, DE, 07747
DE Magdeburg, DE
DE Mainz, DE, 55131
DK Hvidovre, DK, 2650
ES Barcelona, ES, 08036
ES Barcelona, ES, 08041
ES Madrid, ES, 28034
ES Santander, ES, 39008
ES Sevilla, ES, 41013
ES Zaragoza, ES, 50009
NL Amsterdam, NL, 1105 AZ
US, AL Birmingham, AL, US, 35233
US, CA Pasadena, CA, US, 91105
US, CA San Diego, CA, US, 92103
US, CA San Francisco, CA, US, 94115
US, CA West Hollywood, CA, US, 90048
US, LA New Orleans, LA, US, 70115
US, MN Rochester, MN, US, 55905
US, NY New York, NY, US, 10016
US, SC Charleston, SC, US, 29425
US, VA Charlottesville, VA, US, 22903
US, VA Richmond, VA, US, 23298
US, WI Milwaukee, WI, US, 53226